Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine (Nasdaq: EDIT) announced management will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference and Barclays 28th Annual Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Editas Medicine (Nasdaq: EDIT) announced management will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference and Barclays 28th Annual Global Healthcare Conference. Both appearances are fireside chats; dates, times, and locations are listed. Live webcasts and archived replays will be available via the company’s Investors website for approximately 30 days after each event.
Investors can view the March 2, 10:30 a.m. ET session in Boston and the March 12, 8:00 a.m. ET session in Miami Beach via the company’s investor webcasts.
Details
News Market Reaction – EDIT
On Feb 23, the day this news came out, EDIT closed 5.59% above the previous close.
Data tracked by StockTitan Argus for the Feb 23 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in March:
- TD Cowen 46th Annual Health Care Conference
Format: Fireside Chat
Date: Monday, March 2
Time: 10:30 a.m. ET
Location: Boston, MA
- Barclays 28th Annual Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, March 12
Time: 8:00 a.m. ET
Location: Miami Beach, FL
To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Investor and Media Contacts: ir@editasmed.com media@editasmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.